# Rhu-pGSN for Severe Covid-19 Pneumonia

> **NCT04358406** · PHASE2 · COMPLETED · sponsor: **BioAegis Therapeutics Inc.** · enrollment: 64 (actual)

## Conditions studied

- Sars-CoV2

## Interventions

- **DRUG:** Recombinant human plasma gelsolin (Rhu-pGSN)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04358406
- **Lead sponsor:** BioAegis Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-30
- **Primary completion:** 2021-05-25
- **Final completion:** 2022-01-28
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04358406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04358406, "Rhu-pGSN for Severe Covid-19 Pneumonia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04358406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*